Soo-Zin Kim-Wanner
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Soo-Zin Kim-Wanner has a total of 60 co-authors. Here are the top co-authors by number of shared publications:
Petra Neuser
Landesauswertungsstelle des Hessischen Krebsregisters, Hessisches Landesamt für Gesundheit und Pflege, Frankfurt, Deutschland
3 shared publications- Alice Nennecke
Hamburg Cancer Registry, Hamburg, Germany
2 shared publications - Bernd Holleczek
Krebsregister Saarland, Saarbrücken, Deutschland
2 shared publications - Ian Wittenberg
Cancer Registry Saxony-Anhalt, 06112 Halle (Saale), Germany
2 shared publications Klaus Kraywinkel
Robert Koch-Institut, Berlin, Deutschland
2 shared publications- Alexander Katalinic
Institute of Social Medicine and Epidemiology, University of Luebeck, Luebeck, Germany
1 shared publication
Latest Publications
- Open Access
- 28 October 2026
- Published by Elsevier in ESMO Real World Data and Digital Oncology
- Vol. 14
Population-wide implementation of comprehensive cancer registration in Germany—overview article on current status quo and future perspectives
- 28 October 2026
- Published by Elsevier in ESMO Real World Data and Digital Oncology
- Vol. 14
Open AccessPopulation-wide implementation of comprehensive cancer registration in Germany—overview article on current status quo and future perspectives
- Open Access
- 17 September 2026
- Published by Elsevier in ESMO Real World Data and Digital Oncology
- Vol. 14
From free text to structured genomics: future-proofing cancer registries for precision oncology
- 17 September 2026
- Published by Elsevier in ESMO Real World Data and Digital Oncology
- Vol. 14
Open AccessFrom free text to structured genomics: future-proofing cancer registries for precision oncology
- Open Access
Octogenarians and Pancreatic Cancer: Is Surgery Always the Right Choice?
Background: Demographic change is leading to an increasing portion of octogenarians with pancreatic ductal adenocarcinoma (PDAC). Surgery remains a central component of curative-intent treatment. Nevertheless, it carries a risk of potentially life-threatening complications and high morbidity. Whether octogenarians benefit from surgery remains unclear. Methods: Using data from the clinical cancer registries of the 10th National Oncology Quality Conference of the ADT, we divided all patients with PDAC diagnosed between 2015 and 2023 into three age groups (≤65 years, n = 944; 66–79 years, n = 1535; ≥80 years, n = 537) and compared demographics, histopathology, treatment patterns, and survival data. Results: We observed an increasing proportion of octogenarians over the years from 15% in 2015 to 32% in 2023. While they were diagnosed with more favorable tumor stages, they more often received palliative chemotherapy (28% vs. 18%/19% in the younger cohorts). Only 24% of octogenarians who underwent surgery received adjuvant chemotherapy. Octogenarians had a worse overall and disease-free survival and 90-day mortality than the younger age groups. Furthermore, octogenarians with surgery or chemotherapy with curative intent alone had survival rates comparable to patients with palliative care. Conclusions: Octogenarians largely do not benefit from surgery alone. As only a quarter of octogenarians received adjuvant chemotherapy after surgery, neoadjuvant concepts might be useful for selecting patients who are fit enough to undergo and benefit from multimodal treatment.
Open AccessOctogenarians and Pancreatic Cancer: Is Surgery Always the Right Choice?
Background: Demographic change is leading to an increasing portion of octogenarians with pancreatic ductal adenocarcinoma (PDAC). Surgery remains a central component of curative-intent treatment. Nevertheless, it carries a risk of potentially life-threatening complications and high morbidity. Whether octogenarians benefit from surgery remains unclear. Methods: Using data from the clinical cancer registries of the 10th National Oncology Quality Conference of the ADT, we divided all patients with PDAC diagnosed between 2015 and 2023 into three age groups (≤65 years, n = 944; 66–79 years, n = 1535; ≥80 years, n = 537) and compared demographics, histopathology, treatment patterns, and survival data. Results: We observed an increasing proportion of octogenarians over the years from 15% in 2015 to 32% in 2023. While they were diagnosed with more favorable tumor stages, they more often received palliative chemotherapy (28% vs. 18%/19% in the younger cohorts). Only 24% of octogenarians who underwent surgery received adjuvant chemotherapy. Octogenarians had a worse overall and disease-free survival and 90-day mortality than the younger age groups. Furthermore, octogenarians with surgery or chemotherapy with curative intent alone had survival rates comparable to patients with palliative care. Conclusions: Octogenarians largely do not benefit from surgery alone. As only a quarter of octogenarians received adjuvant chemotherapy after surgery, neoadjuvant concepts might be useful for selecting patients who are fit enough to undergo and benefit from multimodal treatment.
- 21 August 2025
- Published by Springer Nature in Die Onkologie
- Vol. 31 (10) , 954-960
Flächendeckende Anwendung von Immuntherapien in Deutschland
- 21 August 2025
- Published by Springer Nature in Die Onkologie
- Vol. 31 (10) , 954-960
Flächendeckende Anwendung von Immuntherapien in Deutschland
- 11 November 2024
- Published by Springer Nature in Die Onkologie
- Vol. 30 (12) , 1-5
Faktenblatt: Epidemiologie der bösartigen Neubildungen des Magens in Deutschland 2020 bis 2021
- 11 November 2024
- Published by Springer Nature in Die Onkologie
- Vol. 30 (12) , 1-5
Faktenblatt: Epidemiologie der bösartigen Neubildungen des Magens in Deutschland 2020 bis 2021
- Open Access
- 6 September 2024
- Published by Elsevier in Cancer Epidemiology
- Vol. 93, 102659
Incidence and survival of patients with malignant pancreatic neuroendocrine neoplasms in Germany, 2009–2021
- 6 September 2024
- Published by Elsevier in Cancer Epidemiology
- Vol. 93, 102659
Open AccessIncidence and survival of patients with malignant pancreatic neuroendocrine neoplasms in Germany, 2009–2021
- 1 April 2023
- Published by Springer Nature in Die Onkologie
- Vol. 29 (4) , 281-286
Fact sheet: epidemiology of myeloproliferative neoplasms and myelodysplastic syndrome in Germany from 2017 to 2019
- 1 April 2023
- Published by Springer Nature in Die Onkologie
- Vol. 29 (4) , 281-286
Fact sheet: epidemiology of myeloproliferative neoplasms and myelodysplastic syndrome in Germany from 2017 to 2019